Photo-illustration by Newsweek/Getty

Alexis Kayser

By Alexis Kayser

Healthcare Editor

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


Hims & Hers—the virtual care platform with about 2.5 million subscribers—will now offer laboratory testing through Quest Diagnostics.

Customers will have access to more than 120 biomarker tests across 10 markets of health and longevity: heart health, liver health, metabolic health, immune defense, hormone health, thyroid health, inflammation and stress, nutrients, kidney health and blood.

Hims & Hers believes that this offering will align with consumer preferences, according to Dr. Pat Carroll, the company’s chief medical officer. Patients want more data to help inform their health decisions—but with a national shortage of primary care physicians, many find it challenging to access providers who can order preventative screenings. They're now looking to bypass the complicated traditional medical system, seeking answers and interpreting results on their own terms.

Read More on Health Care

“People are now much more aware of their own health, and they want to be more proactive about it and move away from this paternalistic system that I practiced in for years, [where] the doctor says something and [the patient] follows the doctor’s instructions,” Carroll, a primary care doctor by training, told Newsweek in an exclusive interview. “People are reading a lot more online about their own health care.”

Carroll hopes that by making it easier for patients to access laboratory testing and results, Hims & Hers will “empower them” to “make informed medical decisions” and “advance their own health care.”

Hims & Hers customers can choose from two blood testing plans, paying $199 to test 50 blood biomarkers or $499 to test more than 120. (Newsweek)

...

Demand for laboratory services is on the rise, according to the Centers for Disease Control and Prevention (CDC). Approximately 14 billion lab tests are conducted in the United States each year, and 70 percent of medical decisions depend on them, per the agency.

But doctors aren’t the only ones who making decisions based off bloodwork. Patients also want faster access to their lab results, with nearly 96 percent indicating that they would prefer to receive non-normal results in their online patient portal as soon as possible—even if they arrive before a doctor can analyze them, according to a recent survey published in JAMA Network Open.

Plus, patients are increasingly demanding to initiate tests on their own. National laboratory networks, including Quest Diagnostics and Labcorp, have added “on-demand” options that allow patients to pay for certain workups out of pocket, without physician oversight. In 2022, Quest reported more than 900,000 consumer-initiated test requisitions, leading them to expand their menu for these services throughout 2023 and 2024.

Through Hims & Hers’ model, patients will be able to choose from two blood testing plans. The base offering includes one yearly blood draw that assesses 50 biomarkers for a $199 fee. If patients opt for the advanced offering, they’ll pay $499 for two yearly blood draws that capture more than 120 biomarkers.

Under both plans, patients’ results will be reviewed by Hims & Hers medical providers. (There are currently more than 2,000 providers on the platform.) They might recommend treatment on the platform, if it’s available, or refer them elsewhere to address immediate concerns.

“Our providers review the results, and then on our app, we actually give [customers] clear direction of what's normal, what's not normal, what needs to be addressed soon, versus what can wait,” Carroll said, “and then we provide education, both on our app, but also from our providers [who conduct] outreach with the results to guide them to where they need to be.”

Laboratory tests will be conducted at Quest Diagnostics, which has about than 2,000 locations across all 50 states. Results can typically be expected within two weeks of the test, according to Hims & Hers.

Close-up of a sign for Quest Diagnostics' laboratory in Lafayette, California, on April 9, 2022. (Smith Collection/Gado/Getty Images)

...

Hims & Hers is entering an increasingly competitive laboratory services environment. The direct-to-consumer lab testing market was valued at $3.62 billion in 2025 and is expected to grow to nearly $6 billion by 2030.

Earlier this month, the wearable technology company Oura announced on-demand health panels, offering personalized results and AI-powered analysis through its app. Other direct-to-consumer testing companies are showing promise, too. The virtual platform Superpower raised $30 million in its Series A funding round this spring, and recently launched a $199 annual membership with access to more than 100 biomarker tests each year (more than double the number of biomarkers that Hims & Hers customers will get for the same price). And Forum Health, which launched a “Labs Direct” offering in 2023, claimed a spot on that year’s Inc. 500 list as one of the fastest growing, privately owned companies in the country.

Carroll believes that Hims & Hers will set itself apart from competitors by integrating lab results with its existing treatment offerings, including sexual health, hormone therapy and weight management.

“For all those [other direct-to-consumer laboratory testing] companies, you get the results, and then they're leaving it up to you to connect with the provider to manage abnormal results,” he said. “For us, we have the power of a huge provider group today that already delivers care on things like weight management, which has a significant impact [on blood biomarkers].”

Hims & Hers’ lab offering bookends a turbulent year for the company. Novo Nordisk terminated its partnership with Hims & Hers in June, accusing the platform of illegally selling compounded versions of its weight loss drug Wegovy. Hims & Hers fell short of second quarter earnings expectations, sending stocks tumbling in August.

But since September, Hims & Hers launched multiple new offerings, including oral compounds for low testosterone, treatment plans for perimenopause and menopause and, most recently, options for GLP-1 “microdosing.” The company’s stock rebounded after its third quarter earnings call on November 3, where it reported that it is now in talks with Novo Nordisk to sell Wegovy, and that “subscribers using personalized solutions grew 50 percent year-over-year.”

With so many new offerings on the way, Newsweek asked Carroll how Hims & Hers decides which markets to crack. Is it just throwing spaghetti on the wall to see what sticks, or is there an actual strategy driving these rapid product releases?

Carroll replied that the company knows its place in the health care industry—and that it’s watching consumer trends closely to expand offerings within its wheelhouse.

“We’re not the patient-centered medical home,” Carroll said. “In other words, we’re not going to care for all the conditions a patient may have, particularly more serious chronic illnesses, but we supplement the health care of a patient by providing them affordable access to care, particularly around things like proactive lab testing.”

“We look at, what’s the demand, what’s the need, can we actually act on that need in a safe, responsible way and provide the same quality of care as you could get in brick-and-mortar?” he continued.

“That’s pretty much our sweet spot in health care.”

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines